H.C. Wainwright raised the firm’s price target on MediWound to $28 from $26 and keeps a Buy rating on the shares. The analyst sees NexoBrid driving the company’s growth in 2025 and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDWD:
- Biotech Alert: Searches spiking for these stocks today
- MediWound announces FDA accepted review the sBLA for NexoBrid
- MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
- MediWound secures additional DoD funding to advance NexoBrid for U.S. Army
- MediWound announces peer-review publication of EscharEx
